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Abstract
Recent cross-sectional analyses of HIV-1+ plasmas have indicated that broadly cross-reactive neutralizing antibody
responses are developed by 10%–30% of HIV-1+ subjects. The timing of the initial development of such anti-viral responses
is unknown. It is also unknown whether the emergence of these responses coincides with the appearance of antibody
specificities to a single or multiple regions of the viral envelope glycoprotein (Env). Here we analyzed the cross-neutralizing
antibody responses in longitudinal plasmas collected soon after and up to seven years after HIV-1 infection. We find that
anti-HIV-1 cross-neutralizing antibody responses first become evident on average at 2.5 years and, in rare cases, as early as 1
year following infection. If cross-neutralizing antibody responses do not develop during the first 2–3 years of infection, they
most likely will not do so subsequently. Our results indicate a potential link between the development of cross-neutralizing
antibody responses and specific activation markers on T cells, and with plasma viremia levels. The earliest cross-neutralizing
antibody response targets a limited number of Env regions, primarily the CD4-binding site and epitopes that are not present
on monomeric Env, but on the virion-associated trimeric Env form. In contrast, the neutralizing activities of plasmas from
subjects that did not develop cross-neutralizing antibody responses target epitopes on monomeric gp120 other than the
CD4-BS. Our study provides information that is not only relevant to better understanding the interaction of the human
immune system with HIV but may guide the development of effective immunization protocols. Since antibodies to complex
epitopes that are present on the virion-associated envelope spike appear to be key components of earliest cross-
neutralizing activities of HIV-1+ plasmas, then emphasis should be made to elicit similar antibodies by vaccination.
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Introduction
The initial antibody response to the HIV-1 viral envelope
glycoprotein (Env) manifests itself within the first 2 weeks of
infection and is non-neutralizing [1,2]. Autologous neutralizing
antibodiesdevelopduringthefirstmonthsafterinfection[3,4,5]and
recent studies indicated that approximately 10%–30% of chroni-
cally-infected HIV-1 subjects develop cross-reactive neutralizing
antibody responses of significant breadth [6,7,8]. These latter
responses are the ones an effective vaccine should elicit [9]. Several
studies indicated that the breadth of plasma cross-neutralizing
antibody responses is positively associated with plasma viral load
[6,7,10,11,12],butverylittleisknownaboutthe timecourseofthese
responses. A recent study by van Gils et al, using samples collected
at 2 and 4 years following infection, indicated that a greater number
ofinfectedsubjectsdisplayedcross-neutralizingactivitiesat4thanat
2 years [12]. However, the earliest timing of the development of
such responses was not determined. Defining the timing of
emergence of cross- neutralizing antibody responses following
HIV-1 infection and identifying factors associated with their
development, will advance our understanding of the complex
interaction of HIV-1 with the immune system, will improve our
understanding on how HIV-1 infection leads to immune dysfunc-
tion, and will also be useful to the development of immunization
protocols that hopefully would elicit similar antibody responses.
The epitope specificities of the anti-HIV-1 cross-reactive
neutralizing antibody responses in HIV-1+ plasmas collected
during chronic infection are complex, with many specificities
remaining undefined. Although there is general consensus that
these neutralizing activities rarely target the transmembrane
subunit gp41, but mostly the extracellular gp120 subunit
[7,13,14,15,16,17], there remains quite an uncertainty whether
the overall cross-neutralizing activities of HIV-1+ plasmas are due
to a single, a limited number of, or many different epitope
specificities [7,13,14,15,16,18,19,20,21,22]. The above studies
were conducted with samples from chronically-infected subjects
and very little, if anything, is known about the epitope specificities
of the earliest cross-neutralizing antibody responses in HIV-1+
plasmas. Defining these epitope specificities would be informative
for future immunogen design efforts.
Here we analyzed the cross-neutralizing antibody responses in
longitudinal plasmas collected soon after and up to seven years
PLoS Pathogens | www.plospathogens.org 1 January 2011 | Volume 7 | Issue 1 | e1001251after HIV-1 infection. We found that the subset of HIV-1-infected
subjects that develop cross-neutralizing antibody responses do so
on average within the first 2.5 years of infection, although in rare
cases such responses became detectable as early as 1 year after
infection. Epitope-mapping analyses indicated that the earliest
cross-neutralizing antibody responses target primarily epitopes
within and around the CD4-BS of gp120, or epitopes that are
present on the virion-associated trimeric Env, but not on the
corresponding monomeric gp120 or gp41 Env subunits. In
contrast, the neutralizing activities of plasmas from subjects that
did not develop cross-neutralizing antibody responses, target
epitopes on monomeric gp120, other than the CD4-BS. These
observations are indicative of the presence and long-term survival
of B cells that recognize complex but conserved epitopes on the
viral Env in those HIV-infected subjects that develop cross-
neutralizing antibody responses.
Results
Detection of cross-reactive neutralizing responses as
early as one year following HIV-1 infection
To define the earliest period following HIV-1 infection when
cross-neutralizing antibody responses appear in plasma we
determined the neutralizing activities of plasmas collected within
a few months and up to several years post HIV-1 infection from
anti-retroviral naı ¨ve subjects infected with clade B viruses, against
20 heterologous clade A, B and C primary isolates (Figures 1 and
2). Plasma samples from two independent cohorts were examined.
The samples from the Vanderbilt cohort (VC) were, for the most
part, collected within the first year of infection (Figure 1). The
breadth of cross-neutralizing activity (i.e., the percentage of viruses
neutralized by any given plasma out of the total number of viruses
the plasma was tested against) was minimal (less than 50%), in
agreement with previous observations [2,5]. In most cases, these
‘early’ plasmas efficiently neutralized the ‘easy-to-neutralize’
primary SF162.LS virus, but not other primary viruses examined
here. In the few cases where neutralizing activity against viruses
other than SF162 was observed, the potency of neutralization was
for the most part very weak and the neutralizing activities targeted
clade B viruses. In two cases (subjects VC20017 and VC20027) the
‘early’ plasmas also neutralized a few non-clade B viruses. Plasma
VC20027 collected within the first year of infection neutralized 6/
9 clade B, 3/6 clade C and 1/4 clade A viruses. Plasma sample
collected from subject VC20017 during the first year of infection
neutralized 4/9 clade B viruses, the clade A virus Q259d2.17, and
the clade C viruses ZM214M and Du422.1. These observations
indicate that cross-neutralizing antibody responses begin to
emerge during the first year of HIV-1 infection, but that such
responses are weak in potency and narrow in breadth; rarely
targeting viruses from clades other than the one the patient is
infected with.
In the case of the MGH Acute HIV Infection Cohort (AC),
plasma samples were collected longitudinally within a few months
after infection and up to approximately 7 years post infection, with
an average follow-up of 3.31 years. Here, too, samples collected
during the first year of infection did not display broad cross-
neutralizing activities (Figure 2). In only one case (subject AC128),
a plasma sample collected approximately 1.4 years after infection
neutralized 65% of the heterologous viruses tested (7/10 clade B,
5/6 clade C and 1/4 clade A). A plasma sample collected a year
later from the same subject neutralized 90% of the viruses tested
with greater potency: an indication of a continuous evolution and
increase in the breadth of the cross-neutralizing antibody
responses during the first 2 years of infection in this subject.
Overall, plasma samples from 7/17 subjects (41%) (AC049,
AC053, AC071, AC089, AC128, AC131, and AC180) displayed
cross-neutralizing activities against 50% of the isolates tested
against at some point during the period of observation. Samples
from 5/17 subjects (29%) (AC049, AC053, AC128, AC131, and
AC180) displayed broad cross-neutralizing activities against at
least 75% of the viruses tested at some point during the period of
observation. This percentage is in agreement with numerous
previous reports on the frequencies of broad cross-neutralizing
activities in sera collected during chronic HIV-1 infection [6,7,8].
In these 5 cases, a gradual increase in the breadth of cross-
neutralizing activities was recorded over time, even though
plasmas collected longitudinally from individual subjects did not
always neutralize the same isolates, nor with the same potency.
Such changes in potency by samples collected over time from
individual subjects could be due to changes in the number of
epitopes recognized by the circulating antibodies (i.e., the relative
proportions of NAbs with diverse epitope specificities change over
time), and/or due to changes in the plasma concentrations of
antibodies with epitope specificities that do not change over time.
Collectively, the above results indicate that the mean time it took
for the breadth of cross-neutralizing activities to reach 50% was
2.13 years and the mean time to reach 75% was 3.08 years.
Although the percentage of subjects developing cross-neutralizing
antibody responses increased during the first 3 years of infection,
that percentage did not further increase in year 4 (Figure 3).
Clearly, additional longitudinal analysis is required to determine
whether cross-neutralizing antibody responses increase past that
time.
Factors associated with the emergence of cross-
neutralizing antibody responses
In chronic HIV-1 infection the breadth of serum cross-
neutralizing antibody activities positively correlates with the levels
of plasma viremia [6,7,11,12]. Here, we recorded a positive
correlation (p=0.0026; R=0.3615) between the breadth of the
earliest cross-neutralizing antibody responses in HIV+ plasmas
and the levels of plasma viremia. Because of the association
between plasma viremia and immune activation during early HIV
infection [23], we examined potential associations between the
development of serum cross-neutralizing activities and markers of
immune activation and exhaustion (Figure 4). Specifically, we
Author Summary
A fraction of those infected with HIV develop broadly
neutralizing antibodies (bNAbs) capable of preventing cell-
infection by diverse HIV isolates; the type of antibodies we
wish to elicit by vaccination. Identifying factors associated
with the natural development of bNabs, and defining the
timing of their emergence and their epitope specificities,
will assist the development of more effective immunogens
and vaccination protocols. Here we performed a neutral-
ization screen of plasma samples collected longitudinally
from HIV-1-infected subjects and determined that on
average, cross-neutralizing antibody responses emerge 2–
3 years, but as early as one year, following infection. A
significant portion of the earliest cross-neutralizing anti-
body response to HIV targets epitopes that are present on
the virion-associated trimeric Env spike, but not the
corresponding soluble monomeric versions of that viral
protein. Our study highlights the importance of eliciting by
vaccination antibodies with this type of complex epitope
specificities.
Early Broad Anti-HIV-1 NAbs
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Ki67, CD57, CD38, PD1, and HLADR in subjects that developed
cross-neutralizing antibody responses and those who did not. The
immune activation status of subjects who developed broad cross-
neutralizing antibody responses (at least 75% breadth at some
point during the period of observation) was determined at the
Figure 1. Cross-neutralizing activities in plasmas from the Vanderbilt Cohort. The cross-neutralizing activities of plasmas from the
indicated subjects (PID) were evaluated against the indicated clade B, C and A viruses. The values are the plasma titers at which 50% neutralization
(IC50) was recorded. For clarity this information is color-coded: (blue) IC50,1:100; (orange) 1:100#IC50$1:250; (red) IC50.1:250. With the exception
of SF162.LS (tier 1 virus), all other viruses are tier 2 [58,59,61]. (-): less than 50% neutralization was recorded; YPI: years post-infection; ‘breadth’: the
percent of isolates neutralized by a plasma sample, out of the total number of isolates tested, irrespective of the potency of neutralization [7]. Each
experiment was performed at least two independent times.
doi:10.1371/journal.ppat.1001251.g001
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PLoS Pathogens | www.plospathogens.org 3 January 2011 | Volume 7 | Issue 1 | e1001251Figure 2. Cross-neutralizing activities in plasmas from the MGH Acute HIV infection Cohort. The cross-neutralizing activities of plasmas
from the indicated subjects (PID) were evaluated against the indicated clade B, C and A viruses. The values are the plasma titers at which 50%
neutralization (IC50) was recorded. For clarity this information is color-coded: (blue) IC50,1:100; (orange) 1:100#IC50$1:250; (red) IC50.1:250. With
the exception of SF162.LS (tier 1 virus), all other viruses are tier 2 [58,59,61]. (-): less than 50% neutralization was recorded; YPI: years post-infection;
‘breadth’: the percent of isolates neutralized by a plasma sample, out of the total number of isolates tested, irrespective of the potency of
neutralization [7]. Each experiment was performed at least two independent times.
doi:10.1371/journal.ppat.1001251.g002
Early Broad Anti-HIV-1 NAbs
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were evident: for AC049 at 2.62 year post-infection (ypi), for
AC053 at 3.29 ypi, for AC128 at 1.41 ypi, for AC131 at 1.52 ypi,
and for AC180 at 2.19 ypi. Similar time points of infection were
used for those subjects who did not develop cross-neutralizing
antibody responses (AC093, AC110, AC167, AC183, AC194, and
AC212).
A trend towards higher percentages of CD8+ T cells expressing
Ki67 (p:0.122), CD38 (p:0.0823), and PD1 (p: 0.0823) was
recorded in subjects with breadth. It is likely that, because the
number of subjects who developed cross-neutralizing antibody
responses is small, these differences did not reach statistical
significance. A similar trend towards higher expression of Ki67
(p:0.0823) and CD38 (p:0.0823) was recorded in the case of CD4+
T lymphocytes. A statistically significant difference (P:0.0173) was,
however, recorded in the percent of CD4+ PD1+ T cells between
those subjects that developed cross-neutralizing antibody responses
and those who did not. In addition, we performed correlation
analysis between the degree of breadth and the frequencies of T
cells expressing the various activation markers. A statistically
significant positive association was observed between breadth and
the frequency of CD4+ PD1+ T cells (p: 0.0174, Pearson r:
0.6961), and CD4+ CD38+ T cells (p: 0.0306, Pearson r: 0.6494).
Overall, these results link for the first time the state of immune
activation (within approximately 2 years of infection) to the
development of cross-reactive neutralizing antibody responses.
Epitope specificities of the earliest cross-neutralizing
antibody response
Taking advantage of the availability of longitudinal samples
from the MGH Acute HIV Infection Cohort, we performed
epitope-mapping studies to determine: (a) whether the initial cross-
neutralizing antibody responses developed by subjects infected
with different viruses were due to the emergence of antibodies that
target one or multiple epitopes on heterologous Env, and (b)
whether the initial epitope specificities of cross-reactive neutraliz-
ing antibody responses in HIV-1+ plasmas evolve over time.
Cross-neutralizing activities targeting the transmem-
brane gp41 Env subunit. The extracellular part of the
transmembrane subunit gp41 is immunogenic [24,25] and the
Figure 3. Evolution of the potency and breadth of cross-neutralizing antibody responses. The pie charts represent the evolution of
breadth and potency of serum neutralizing activities in the MGH Acute HIV Infection Cohort. Subjects who developed cross-neutralizing activities
within the first 2 years of infection, but who were not followed longitudinally post that period, were not included in our calculations in the
subsequent years. Samples from 17 subjects were available during the 1
st year of infection, samples from 16 during the 2
nd year, 11 during the 3
rd,
and 7 during the 4
th year.
doi:10.1371/journal.ppat.1001251.g003
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PLoS Pathogens | www.plospathogens.org 5 January 2011 | Volume 7 | Issue 1 | e1001251Figure 4. Immune activation markers and cross-neutralizing antibody responses. The frequencies of (A) CD8+, and (B) CD4+ T cells
expressing the indicated markers in subjects who developed cross-neutralizing antibodies (at least 75% breadth) (AC049, AC053, AC128, AC131 and
AC180) and those who did not (no breadth) (AC093, AC110, AC167, AC183, AC194, AC212) are shown. These frequencies were determined at the
earliest time point when cross-neutralizing antibody responses were evident: for AC049 at 2.62 year post-infection (ypi), for AC053 at 3.29 ypi, for
AC128 at 1.41 ypi, for AC131 at 1.52 ypi, and for AC180 at 2.19 ypi. Similar time points of infection were used for those subjects who did not develop
cross-neutralizing antibody responses.
doi:10.1371/journal.ppat.1001251.g004
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following infection [2]. However, the vast majority of human anti-
gp41 MAbs are non-neutralizing and only a handful of anti-gp41
neutralizing MAbs have been isolated from HIV-1-infected subjects
[26,27,28,29]. Two of these anti-gp41 MAbs, 2F5 and 4E10,
display broad cross-neutralizing activities and they recognize two
distinct epitopes within MPER [26,27]. In between the 2F5 and
4E10 epitopes lies the epitope recognized by a third anti-HIV-1
antibody, Z13, whose breadth of neutralization is much narrower
than those of 2F5 and 4E10 [27,30].
We first performed peptide competition neutralization experi-
ments, during which the plasmas were pre-incubated with a
MPER-derived peptide and then incubated with viruses (JRFL
and TRO.11) (Table 1). MPER-derived peptides block the
neutralizing activities of MAbs 4E10 and 2F5, and have been
used to define the contribution of anti-MPER neutralizing
activities in HIV+ sera [7,13,14,31,32]. Control experiments
confirmed that the MPER peptide specifically competes the
neutralizing activities of the anti-MPER MAbs 2F5 and 4E10, but
not those of neutralizing antibodies to other regions of Env (such
as the anti-gp120 MAbs b12, 2G12, P3C8 and P3E1) (data not
shown). In only one subject (AC131) the MPER-derived peptide
consistently reduced (by a modest 0.3–0.6 Log10) the plasma’s
overall neutralizing activity against both HIV-1 viruses tested,
indicating that the anti-MPER antibodies in this plasma
moderately contribute to its overall anti-HIV-1 cross-neutralizing
potential. Interestingly, the relative contribution of anti-MPER
antibodies to the anti-JRFL and -TRO.11 neutralizing activity
decreased during the period of observation in that subject,
although the breadth of cross-neutralizing activity increased from
45% to 75% during that period.
To better define the epitope(s) within the MPER region targeted
by these antibodies we utilized viruses expressing chimeric HIV-2/
HIV-1 Envs [13,31,33]. These chimeric Envs are based on the
HIV-2 Env 7312A, on which the entire MPER region, or portions
of it, have been replaced by those of the HIV-1 clade B YU2 Env.
Since plasmas isolated from HIV-1-infected subjects rarely
neutralizing HIV-2 isolates, these chimeras are useful tools to
detect the presence of anti-HIV-1 MPER neutralizing antibody
responses [13,31,33]. The MPER sequences of the chimeras used
here are shown in Table 1. As expected, plasma from AC131 was
very effective in neutralizing the C1 chimera, which expresses the
entire HIV-1 MPER region (Table 1). This plasma also potently
neutralized the C8 chimera, which expresses the domain of MPER
encompassing the Z13 and 4E10 epitopes, while it did not
efficiently neutralize the C3 or C4 chimeras, which express the
2F5 and 4E10 epitopes, respectively, of the HIV-1 MPER. Most
likely therefore, this plasma contains neutralizing antibodies whose
epitope(s) overlaps the Z13 and 4E10 epitopes. Overall, these
results indicate that anti-MPER neutralizing antibodies rarely (and
only modestly) contribute to the earliest cross-neutralizing
antibody responses following HIV-1 infection. They are in
agreement with numerous recent studies indicating that anti-
MPER targeted antibodies rarely contribute to the breadth of
cross-neutralizing activities of HIV-1+ sera from chronic infection
[7,13,14,15,16,17,31,32].
We did not investigate whether anti-gp41 antibodies that target
regions other than the MPER were present and contributed to the
early cross-neutralizing activities of the above plasmas. Although
several monoclonal antibodies against the HR1 domain of gp41
have been shown to display anti-HIV neutralizing potentials, such
antibodies are generally not broadly neutralizing [28,34,35].
Table 1. Contribution of anti-MPER antibodies to the plasma’s cross-neutralizing activities.
Log decrease in presence of MPER
d IC50 of HIV2/HIV1 MPER chimeras
g
PID
a YPI
b Breadth
c JRFL TRO.11 C1 (MPER) C3 (2F5) C4 (4E10) C8 (Z13, 4E10)
AC131 2.38 45% 0.48 0.68 .2560 43 119 .2560
3.19 75% 0.39 0.35 .2560 24 157 .2560
AC049 3.64 85% (--)
e (--)
4.39 80% (--) nd
f
AC053 5.31 80% (--) (--)
5.88 60% (--) (--)
AC071 3.34 50% (--) (--)
3.80 40% (--) nd
AC089 1.94 50% (--) (--)
AC093 4.97 35% (--) (--)
AC128 2.47 90% (--) (--)
aPatient ID.
bYears post infection.
cBreadth: the percentage of HIV-1 isolates neutralized by each plasma, out of the total number of isolates the plasma was tested against.
dThe neutralizing activities of plasmas collected at the indicated time points following infection were evaluated against the HIV-1 viruses JRFL and TRO.11 in the
absence or presence of the MPER peptide (NEQELLELDKWASLWNWFDITNWLWYIRKKK). The Log10 decrease in IC50 neutralization titers in the presence of the MPER
peptide is indicated.
eNo affect in the neutralizing activities of plasmas was recorded in the presence of the MPER peptide.
fExperiment not performed.
gThe IC50 neutralizing titers of plasma samples collected from subject AC131, against four HIV2/HIV-1 MPER chimeric viruses are indicated. The MPER amino acid
sequences of the parental strains and the chimeras are as follows: 7312A HIV-2 (QIQQEKNMYELQKLNSWDVFGNWFDLASWVKYIQYGVYIV), YU-2 MPER
(NEQELLALDKWASLWNWFDITKWLWYIKI), 7312A-C1 (QIQQEKNMYELLALDKWASLWNWFDITKWLWYIKYGVYIV), 7312A-C3
(QIQQEKNMYELLALDKWASLWNWFDLASWVKYIQYGVYIV), 7312A-C4 (QIQQEKNMYELQKLNSWDVFGNWFDITKWLWYIKYGVYIV), 7312A-C8
(QIQQEKNMYELQKLNSWASLWNWFDITKWLWYIKYGVYIV). For each chimeric virus, we indicate whether it expresses the 2F5, 4E10, Z13 epitopes, or the entire HIV-1
MPER The core epitopes of 2F5 (ALDKWA), Z13 (WASLWNWFDIT) and 4E10 (NWFDIT) are underlined.
doi:10.1371/journal.ppat.1001251.t001
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subunit. Potentially, the above results suggested that the
earliest cross-neutralizing activities in HIV-1+ plasmas are
primarily targeting the extracellular gp120 subunit. To address
this point, we depleted the anti-gp120 antibodies from six plasmas
(AC049, AC053, AC071, AC128, AC131, AC180) displaying
cross-neutralizing activities, and three of the plasmas (AC098,
AC115, AC212), which only neutralized SF162 (Figure S1).
Although during these depletion experiments we used gp120 from
one clade B virus (SF162), we verified that this treatment
eliminated anti-gp120 antibodies against other gp120s, from
both clade B and clade C viruses (Figure S1). Then, the
neutralizing activities of non-depleted and of the corresponding
gp120-antibody-depleted plasmas were compared against several
clade B and C viruses (the data are summarized in Figure 5A and
representative examples are shown in Figure 6). Removal of the
anti-gp120 antibodies from plasmas with narrow breadth resulted
in complete loss in neutralizing activity. In contrast, removal of the
anti-gp120 antibodies from plasmas with breadth had a diverse
effect on the neutralizing activities of plasmas, depending on the
Figure 5. Contribution of anti-gp120 antibodies to the overall neutralizing activity of HIV+ plasmas. (A) Log10 decrease in neutralizing
activity caused by the elimination of anti-gp120 antibodies, and (B) Log10 decrease in neutralizing activity of plasmas in the presence of D368R. The
values are the average from 2–3 independent experiments in most cases. Light blue: no effect or less than 0.5 Log10 decrease; Yellow: decrease
between 0.5 and 0.9 Log10; Red: over 0.9 Log10 decrease. .1.00: indicates that the depletion of anti-gp120 antibodies from plasma resulted in
complete loss of the neutralizing activity. (--) the experiment was not performed because that particular plasma did not neutralize that particular
virus; nd: experiment was not performed; YPI: years post infection.
doi:10.1371/journal.ppat.1001251.g005
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changes in IC50 titers were recorded or changes smaller than
0.5Log10 in IC50 were recorded. However, in specific cases the
neutralizing activity of given plasma against a given virus was
completely lost when the anti-gp120 antibodies were removed.
That was the case of plasma AC131 and the QH0692 and SF162
viruses (but not other viruses tested); or the case of plasma AC053
and the YU2, REJO and Du422 viruses (but that was not the case
Figure 6. Neutralizing activities of anti-gp120 antibody-depleted plasmas. (A and B) Neutralizing activities of 2 plasmas against the
indicated primary isolates prior to and following the removal of anti-gp120 antibodies, are shown. (A) Plasma AC053 against the TRO.11, JRFL, and
YU2 viruses. (B) Plasma AC131 against TRO.11, JRFL, and Zm214M viruses. TRO.11 (red squares), JRFL (blue triangles), YU2 and ZM214M (green circles).
Patient ID, breadth and years post infection are shown. Undepl: Undepleted plasma. Depleted: plasma depleted from anti-gp120 antibodies. Closed
symbols and solid lines – undepleted plasmas; open symbols and dashed lines – gp120-depleted plasmas. (C) Plasmas from subjects AC098 (squares),
AC115 (inverted triangles), and AC212 (circles) did not display significant breadth and neutralized only SF162.LS (Figure 2). Their anti-SF162.LS
neutralizing activities were determined before and following depletion of the anti-gp120 antibodies. Closed symbols and solid lines: prior to
depletion of anti-gp120 antibodies; open symbols and dashed lines: following the depletion of anti-gp120 antibodies. Each experiment was
performed at least three independent times.
doi:10.1371/journal.ppat.1001251.g006
Early Broad Anti-HIV-1 NAbs
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activities).
It was recently reported by Walker and colleagues that a
significant fraction of cross-neutralizing activities in plasmas
collected during chronic HIV-1-infection are recognizing complex
epitopes on the trimeric Env spike that are not efficiency presented
on (or are absent from) monomeric gp120 [22]. Antibodies with
epitope specificities overlapping those of MAbs PG9 and/or PG16
were defined as being partially responsible for the overall cross-
neutralizing activity of some sera tested in that study. We were
interested in determining whether similar PG9- and PG16-like
antibody specificities are contributing to the earliest cross-
neutralizing anti-HIV-1 activities.
To address this point we generated mutants of HIV-1, on which
the asparagine at position 160 (within the V2 loop) was substituted
by a lysine. Position 160 is critical for the binding and
neutralization of MAbs PG9 and PG16 [22,36], and recently it
was suggested that the sugar molecules present on N160 may also
directly participate in the binding of these two MAbs [37]. In
agreement with these previous studies, we observed that when
asparagine 160 was mutated into a lysine (N160K) or to an alanine
(N160A), MAbs PG9 and PG16 no longer neutralized HIV-1
(TRO.11) (Figure S2). Next, the susceptibilities of the WT and
mutant TRO.11 virus against plasmas were determined, once
gp120-antibodies were eliminated from these plasmas (Table 2).
We selected plasmas from subjects AC053, AC131 and AC181,
since removal of anti-gp120 antibodies from those samples had a
minimal effect on their anti-TRO.11 neutralizing activities
(Figure 5A). In all cases a decrease of that plasmas’ neutralizing
activity was recorded in the case of the N160K mutations.
However, the N160A mutation had no effect on the neutralizing
activity of the same plasmas. Combined, the results indicate that
the sugars at position 160 are not part of the epitope recognized by
these antibodies. Potentially, they suggest that the nature of the
amino acid at position 160 is very relevant to the neutralizing
activity of the earliest cross-neutralizing antibody response in HIV-
1+ plasmas. In summary, our results suggest that the earliest cross-
neutralizing antibody response to HIV-1 includes antibodies
whose epitopes on the virion-associated Env spikes are overlap-
ping, but are not identical to those of MAbs PG9 and PG16.
Epitope-specificities on monomeric gp120. We
performed epitope-mapping analysis to define the regions within
monomeric gp120 that were targeted by cross-reactive
neutralizing antibody responses in certain plasmas. Usually, such
epitope-mapping analysis studies are performed by incubating
HIV-1+ plasmas with soluble peptides derived from the variable
regions of the extracellular HIV-1 Env subunit gp120 [7,13,14].
However, soluble peptides do not accurately represent the
conformations of the variable regions of HIV-1 Env and thus do
not accurately report on the contribution of antibodies that
recognize conformational epitopes within the variable regions. To
deal with this limitation we developed a competition neutralization
assay based on a variant of monomeric gp120, termed D368R.
The D to R mutation at the conserved position 368 within the
CD4-BS abrogates the binding of CD4 and of most known anti-
CD4-BS MAbs to gp120 (with a few exceptions; see below), while
it does not affect the binding of antibodies that target epitopes
outside the CD4-BS [7,15,19]. Because D368R does not bind
cellular CD4, it does not interfere with the ability of the virus to
enter CD4+ target cells during in vitro neutralization assays. We
confirmed that D368R competes the neutralizing activities of
known MAbs that recognize epitopes outside the CD4-BS, such as
P3C8 (anti-V1), P3E1 and 447-52D (anti-V3) [38,39] and 2G12,
which recognizes a conformational epitope made of mannose
residues [40,41,42] (Figure S3A). D368R had no effect on the
neutralizing activities of the anti-CD4-BS MAb b12 or of CD4-
IgG2 (Figure S3B).
We next examined if the neutralizing activities of the above-
described plasmas were affected (and to what extent) by the
presence of D368R (the data are summarized in Figure 5B and
representative examples are shown in Figure S4). The neutralizing
activities of the three plasmas (AC098, AC115, and AC212) with
narrow breadth were significantly reduced in the presence of
D368R; an indication that the anti-SF162 neutralizing activities of
these plasmas are due to antibodies that primarily target epitopes
outside the CD4-BS. In contrast, the cross-neutralizing activities of
plasmas with breadth were either not affected or only modestly
reduced by D368R. The exception was plasma AC053, whose
anti-YU2 neutralizing activity was significantly reduced by
D368R. This result suggests that the anti-YU2 neutralizing
activity of this plasma (but not its neutralizing activity against
any other viruses tested) is due to antibodies that recognize
epitopes on gp120 located outside the CD4-BS.
As expected, in the cases where depletion of the anti-gp120
antibodies had no or only minimal effect on the neutralizing
activity of a plasma sample against a set of viruses, the D368R
protein had a similar effect. In cases, however, where the
neutralizing activity of plasma against a particular virus was
significantly affected by depletion of the anti-gp120 antibodies, our
results indicate that the major fraction of anti-gp120 antibodies
responsible for that neutralizing activity was due to anti-CD4-BS
antibodies. This is the case for example of plasmas AC049,
AC053, AC128, and AC180 against JRFL, of plasma AC053 (3.29
ypi) against YU2, or plasmas AC053 (3.29 ypi), AC131 (3.19 ypi),
and AC180 against the QH0692 virus.
Here we need to clarify that although the D368R mutation
abrogates the binding of most known anti-CD4-BS antibodies, it
does not abrogate the binding of all such antibodies. Corti et al
[28] recently discussed the binding and neutralizing properties of
such a MAb, HJ16. In addition, Scheid et al [16] identified a
group of anti-HIV Env antibodies generated during infection,
termed anti-gp120 core, whose epitopes overlap part of the CD4-
BS and whose binding is not affected by the D368R mutation.
Thus, anti-core antibody specificities in HIV-1+ plasmas will be
‘removed’ if the plasmas are incubated with D368R. Potentially,
the fraction of the plasma neutralizing activities that was
‘eliminated’ in the presence of D368R could be due to anti-core
antibodies.
Longitudinal evolution of anti-D368R neutralizing
activities. With the above caveats in mind, we examined
Table 2. Percent reduction in neutralizing activity of gp120-
depleted plasmas due to amino acid substitutions at position
N160.
Patient ID YPI
a Breadth TRO.11 N160K TRO.11 N160A
AC053 5.31 80% 36%
b (--)
c
AC131 3.19 75% 53% (--)
AC180 2.19 75% 25% (--)
Gp120-depleted plasmas were tested for neutralization of TRO.11 N160
mutants.
aYears post infection.
b% neutralizing activity is the % reduction in IC50 of mutant compared to wild
type.
cNo difference between neutralization of wild type and mutant TRO.11.
doi:10.1371/journal.ppat.1001251.t002
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epitopes on the D368R protein evolve over periods of time during
which the breadth of cross-neutralization increases. We thus
performed D368R competition neutralization experiments with
plasmas collected longitudinally from subjects who gradually
developed breadth (Figure 7). In the vast majority of cases, the
neutralizing activities of plasmas remained minimally affected by
D368R over several years of observation, as the breadth of cross-
neutralization increased. The exception was plasma AC053 and
virus YU2. Here, the presence of D368R had a modest (less than a
0.5 Log10 decrease in IC50) on the anti-YU2 neutralizing activity
at 3.29 years following infection when breadth was less than 50%,
but in the subsequent years, when breadth varied between 60%
and 80%, the anti-YU2 neutralizing activity was significantly
reduced (,1Log10 or more decrease in IC50). In this particular
case, therefore, the anti-YU2 neutralizing activity of this plasma
gradually focused on epitopes present on D368R. This ‘focusing’
was however only observed for YU2 and not for other viruses
tested, such as JRFL, TRO.11, or REJO.
Discussion
It is now recognized that 10–30% of HIV-1 chronically infected
subjects develop cross-neutralizing antibody responses of signifi-
cant breadth [6,7,8,12]. We and others have previously discussed
that the duration of HIV infection is positively associated with the
breadth of cross-neutralizing antibody responses [6,7,11,12]. Here
we show that such anti-viral responses become detectable in the
blood of these subjects, on average, at 2.5 years after infection. In
rare cases, cross-neutralizing antibodies appear as early as 1 year
post-infection. A recent study indicated that the development of
cross-neutralizing antibody responses does not delay the onset of
AIDS [43], however, it is currently unknown whether an unusually
early emergence of such responses will offer a long-term clinical
benefit to the patient or not. The observation that the
development of cross-neutralizing antibody responses is associated
with higher levels of plasma viremia potentially indicates a more
efficient viral escape from autologous anti-viral responses (neu-
tralizing antibody responses and/or cellular-mediated anti-viral
responses) in those subjects that eventually develop cross-
neutralizing antibodies. Our data indicate that those subjects
who develop cross-neutralizing antibodies have higher frequencies
of CD4+ T expressing PD1. This observation is intriguing and
potentially of high importance. A fraction of CD4+ T cells that
express high levels of PD1 (termed follicular T helper cells, TFH)
have a distinct gene expression profile from other effector T cells
and develop independently of the classic TH1 or TH2 lineages
[44,45] They are not ‘exhausted’, they secrete IL-4 and IL-21 for
extended periods of time, and they are crucial for the formation of
germinal centers and the proliferation and survival of circulating
plasma cells [46]. One possible reason for the development of
broad neutralizing antibody responses in only a subset of HIV-1-
infected subjects is that optimal interactions between the TFH and
B cells are taking place in those subjects who develop such
antibody responses, while the TFH-B cell interactions are limited
by the smaller number of TFH cells in those subjects who do not
develop such responses. Clearly, follow up studies are required to
determine whether the CD4+PD1+ T cells found in the periphery
Figure 7. Contribution of anti-CD4-BS antibodies in the overall neutralizing activities of plasmas collected longitudinally. The values
indicate the Log10 decrease in neutralizing activity in the presence of the D368R construct. The values are the average from 2–3 independent
experiments in most cases. The color-coding is the same as in Figure 5. (--) the experiment was not performed because that particular plasma did not
neutralize that particular virus; YPI: years post infection. Cross-neutralizing antibodies that bind the CD4-BS do not recognize the D368R mutant [19],
thus, the majority of the neutralizing activities that remain in the plasmas that have been incubated with D368R most likely are due to cross-
neutralizing antibodies that bind the CD4-BS. There are some exceptions, which are discussed in the Results section.
doi:10.1371/journal.ppat.1001251.g007
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development of cross-neutralizing antibody activities impacts the
rate of disease progression.
The subjects examined here were infected with clade B HIV-1
viruses and it is not known whether the timeline for the emergence
of cross-neutralizing antibody responses in non-clade B HIV-1
infections is similar, or whether infection with a particular HIV-1
subtype elicits an earlier or a delayed development of cross-
neutralizing antibody responses. In the ‘early’ cases examined
here, 29% of subjects developed cross-neutralizing antibody
responses. This percentage is in agreement with several previous
studies conducted with sera collected during chronic infection
[6,7,8]. Potentially our data, in combination with data on the
frequency of broad cross-neutralizing antibody responses in sera
collected during chronic HIV-1 infection [7,8,47], suggest that if
cross-neutralizing antibody responses are not generated during the
first 2–3 years of infection, they may not emerge later. However,
further follow up of these subjects is required to address this
important point. It is currently unknown whether the emergence
of cross-neutralizing antibody responses, at that particular time
period of HIV-1 infection, in only approximately a third of those
infected, is the result of a stochastic event or due to genetic
predisposition, and whether it is related to particular evolutionary
pathways the virus follows in response to other types of anti-viral
immune responses.
In agreement with publications with sera from chronic HIV-1
infection [13,22], we found that the earliest cross-neutralizing
antibody response targets only a few regions of Env. It appears,
therefore, that a few Env regions are targeted early and late during
HIV-1 infection by cross-neutralizing antibodies. The fine
specificities of such antibodies within these Env regions may
evolve over time.
A significant portion of, or the entire, ‘early’ cross-neutralizing
antibody response was due to antibodies that target virion-
associated Env, rather than epitopes present on monomeric gp120
or gp41. The fact that the antibodies that bind such complex
epitopes were elicited in response to infection by viruses unrelated
to the heterologous viruses used to assess the cross-neutralizing
potentials of HIV-1+ plasmas is strongly suggestive that these
epitopes are common and most likely present on the viruses
circulating even in those subjects who do not develop such
antibody responses.
Since such epitopes are conserved among diverse viruses, we
assume that they are also present on the transmitted viruses. Then
why is the appearance of antibodies that target these epitopes
delayed by 2–3 years? Potentially, antibodies that recognize
epitopes which are exclusively present on the virus but not the
monomeric form of HIV-1 Env could very well be generated
earlier following infection, but may specifically target the
autologous virus. In fact, MAbs with such complex epitope
specificities that display only autologous virus neutralizing
activities, or activities only against SF162 and related viruses,
have been isolated from SHIV-infected macaques and from a
chronically HIV-1-infected human [48,49]. As infection progresses
and in response to a continuous viral evolution, the B cell response
to such complex epitopes may also evolve, and this evolution may
eventually lead to the generation of antibodies with broader cross-
neutralizing activities [22,36].
The fact that anti-CD4-BS antibodies contribute to the initial
cross-neutralizing activities of diverse HIV-1+ plasmas is not
surprising since the CD4-BS is one of the most conserved regions
of the HIV-1 Env. Numerous studies have already reported the
contribution of such antibodies in defining the cross-neutralizing
activities of plasmas collected during chronic HIV-1 infection
[7,13,14,15,18,19]. However, anti-CD4-BS antibodies are present
in plasmas with and without ‘breadth’, and several anti-CD4-BS
MAbs displaying very narrow cross-neutralizing activities have
been isolated from HIV-1-infected individuals [50,51]. Presently,
it is not known why only a subset of HIV-1-infected subjects
generates anti-CD4-BS antibodies that are cross-neutralizing,
while the majority of subjects generate anti-CD4-BS antibodies
of narrow neutralizing breadth. The angle of recognition of the
CD4-BS by anti-CD4-BS antibodies with narrow and broad
neutralizing activities is different [52], which implies that the CD4-
BS is recognized differently by the B cell receptors (BCRs) of
subjects who develop cross-neutralizing anti-CD4-BS antibodies
and the BCRs of subjects who develop anti-CD4-BS antibodies of
narrow neutralizing activities.
It is important to note that a fraction of the cross-neutralizing
activities in some subjects could be adsorbed on both gp120 and
the D368R mutant. Such specificities may be similar to those
reported by Scheid et al [16] and more recently by Pietzsch et al
[53] that target the ‘core’ part of gp120. Overall therefore, our
data indicate that the ‘earliest’ cross-neutralizing antibody
response to HIV is primarily comprised of antibodies that target
the CD4-BS, the core of gp120, and epitopes present on the
trimeric Env. The positive association, however, between plasma
viremia levels and the breadth of the earliest cross-neutralizing
antibody responses suggests that HIV is able to escape the action
of the antibodies that recognize conserved regions of Env. Viral
escape from antibodies that preferentially bind the Env trimeric
spike may involve changes in the V1V2 region of Env, since the
epitopes of this type of antibodies include elements of the V1V2
Env region [22,36]. In fact, the V1V2 region of Env undergoes
extensive alterations (including increases in length and in
glycosylation) early following infection [54,55,56]. These changes
are associated with early escape from autologous neutralizing
antibody responses. Our data suggest that such changes may also
be involved in the escape from the early cross-neutralizing
antibody responses.
Our results provide information that may guide the develop-
ment of effective immunization protocols. Since antibodies to
complex epitopes that are present on the virion-associated
envelope spike appear to be key components of the earliest
cross-neutralizing activities of HIV-1+ plasmas, then emphasis
should be made to elicit similar antibodies by vaccination. As a
first step, HIV envelope glycoproteins that readily display such
complex epitopes must be identified and tested as immunogens.
However, if the development of such cross-neutralizing antibodies
is somehow linked to genetic factors, then the outcome of
immunizations with such immunogens will largely depend on
the population the immunogens are evaluated, since only those
vaccinees with the appropriate genetic makeup will respond
appropriately.
Materials and Methods
Cohorts
Patients from the Vanderbilt University and the Ragon Institute
of Massachusetts General Hospital ‘acute / early’ HIV infection
cohorts (also referred to ‘primary’ cohorts) were used in this study.
The subjects selected for the present study were infected with clade
B HIV-1, had no AIDS-defining illnesses, and were not on
antiretroviral therapy at the time of sample collection. In the
MGH Acute HIV Infection Cohort, ‘primary infection’ was
defined by detectable HIV RNA in the presence of either (i) a
negative p24 ELISA, or (ii) a positive ELISA but evolving WB, or
(iii) documented negative HIV ELISA within past 6 months. The
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mostly during the first year of seroconversion. All early infection
subjects in this cohort had a documented negative HIV antibody
test within one year of their first positive western blot result. In the
case of the ‘MGH Acute HIV Infection Cohort’ the date of
infection was known and samples were collected longitudinally
from a few months post infection to up to 7 years post infection. In
total, 53 plasma samples (collected longitudinally up to 2.5 years
post-infection) from 21 HIV+ subjects from the ‘Vanderbilt
Cohort’ and 69 plasma samples from 17 HIV+ subjects from the
‘MGH Cohort’ were evaluated.
Ethics statement
The Ragon Institute’s and Vanderbilt University’s Institutional
review boards approved the study. Written informed consent was
provided by all study participants and/or their legal guardians.
The data were analyzed anonymously.
Plasma antibody adsorptions to monomeric gp120 or
gp41
Plasma anti-HIV Env antibodies were adsorbed on beads
coated with either recombinant SF162 gp120 or HxB2 gp41
(amino acids 541–682, Viral Therapeutics, Inc Ithaca NY) as
previously described [7,19]. The proteins were coupled to MyOne
Dynabeads Tosylactivated (Invitrogen) following the manufactur-
er’s instructions. Briefly, 40 mg of magnetic beads were reacted
with 1 mg protein ligand overnight at 37uC with gentle rotation.
After collecting the beads on a magnet, the supernatant was
removed and the beads were incubated overnight at 37uC in PBS,
0.5% BSA, 0.05% Tween 20. The magnetic beads were washed
twice with PBS, 0.1% BSA, 0.05% Tween 20, and stored at 4uCi n
the same buffer, with the addition of 0.02% Sodium Azide. Bead-
coupled Env proteins were tested for antigenic integrity by flow
cytometry using known MAbs b12, 447–52D, 2G12, IgG-CD4,
and 4E10, followed by detection with goat-anti-human-IgG-FITC
secondary antibody (data not shown). Mock adsorption/elution
experiments using several anti-HIV Env MAbs at a concentration
of 10 mg/ml in naı ¨ve plasma were performed as a positive control
(data not shown). 500ml of plasma, diluted 1:5 in DMEM/
10%FBS, were incubated with 200ml Env protein-coupled beads at
room temperature for 120 min with gentle rotation. The samples
were placed on a magnet and the beads were isolated.
The antibodies bound to the bead-coupled Env proteins were
eluted in a series of increasingly acidic solutions as previously
described [19]. The beads from each serial adsorption were
combined and incubated in 0.1M Glycine-HCl, pH 2.7 for
30 seconds with vortexing. The beads were collected by brief
centrifugation and held in place by a magnet. The supernatant was
removed and adjusted to pH 7.5 with 1M Tris (pH 9.0). The
process was repeated with the beads in 0.1M Glycine-HCl, pH 2.3
and then again in pH 1.7. The final supernatants were buffer-
exchanged in PBS and washed over a 30kD Amicon Ultra
centrifugation concentrator (Millipore). Concentration of immu-
noglobulin was determined by absorbance at 280 nm (NanoDrop
Spectrophotometer ND-1000, Thermo). The depleted plasmas
and the antibodies that were eluted from gp120-coated beads were
tested by ELISA for reactivity to gp120, and for neutralizing
activity.
Neutralization assays
The neutralizing activities of plasmas were determined using the
Tzm-bl-based neutralization assay [57]. Briefly, plasma dilutions
(starting at 1:20) were pre-incubated with single-round competent
virions (pseudovirus) for 60 minutes at 37uC. The plasma /
pseudovirus mixture was added to TZM-bl cells (3000 cells per
well in a 96-well plate) for 72 hrs at 37uC. The supernatant was
removed and 100ml of Steady-Glo Luciferase Assay Substrate
(Promega) was added to each well. Plates were incubated for
15 minutes at room temperature and 75ml of the lysate was
transferred to micro titer plates. The cell-associated luciferase
activity for each well was determined on a Fluoroscan Luminom-
eter (Thermo). Percent neutralization was calculated at each
plasma dilution as the percent inhibition of viral entry by the
plasma sample compared to the absence of plasma. For each
plasma/virus combination tested, a neutralization curve (percent
neutralization versus plasma dilution) was generated using
GraphPad Prism version 4.03 for Windows (GraphPad Software,
San Diego California, USA), and the plasma dilution at which
50% neutralization was recorded (IC50) was determined by
transforming the data to a log10 scale with fitted sigmoidal dose-
response curves.
Neutralization breadth of a plasma sample is defined as the
percent (0%–100%) of the 20 isolates neutralized by that sample.
All plasmas were tested against single round competent virions
expressing Envs from 10 Clade B, 6 Clade C and 4 Clade A
primary viruses. The clade B SF162.LS (EU123924), JRFL
(U63632) and YU2 (M93258) viruses were isolated during chronic
HIV-1 infection and the remaining isolates were isolated during
acute infection, with published accession numbers [58,59,60,61].
All plasma samples were also screened for non-HIV-specific
neutralization using the murine leukemia virus (MLV) pseudo-
typed into the HIV backbone. Neutralization activity was not
detected against MLV at 1:20 by any of the plasma samples (data
not shown).
In certain cases, competition neutralization experiments were
performed in the presence of the D368R gp120 or an MPER-
derived peptide. Serially diluted MAbs or HIV+ plasmas were pre-
incubated with D368R (25 mg/ml) or the MPER peptide (10 mg/
ml) for 1 hour at 37uC and then the mixture was incubated with
virus for another hour at 37uC, and subsequently with cells as
described above. The fold decrease in log10 IC50 neutralization
titers of each plasma tested against each virus in the presence of
D368R or the MPER peptide was determined.
Statistical analysis
Logarithmic transformation was used for viral load, and
nonparametric regression with two-tailed p-value analysis was
used to determine correlations between the breadth of cross-
neutralizing antibody responses in HIV-1+ plasmas and plasma
viremia levels. Mann-Whitney Test and Pierson correlation and
linear regression analysis were used to determine correlations
between immune activation and breadth of neutralizing activities.
Supporting Information
Figure S1 Depletion of anti-gp120 antibodies. The indicated
plasmas were depleted from their anti-gp120 antibodies, and their
anti-gp120 reactivities prior to and following depletion are shown.
The anti-gp120 reactivities were evaluated against 4 heterologous
gp120s: (A) SF162.LS, (B) JRFL, (C) QH069.42, and (D) Du422.1.
Black lines: undepleted plasmas; blue lines: gp120-depleted
plasmas. Years post infection (time following infection he plasmas
were collected) and breadth are indicated in parenthesis in (A) next
to each subjects ID.
Found at: doi:10.1371/journal.ppat.1001251.s001 (0.56 MB TIF)
Figure S2 Effect of N160 mutation on the neutralizing activities
of MAbs PG9 and PG16. The neutralizing activities of MAbs (A)
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TRO.11; N160K: TRO.11 with the asparagine at position 160
mutated to a lysine; N160A: TRO.11 with the asparagine at
position 160 mutated to an alanine.
Found at: doi:10.1371/journal.ppat.1001251.s002 (0.19 MB TIF)
Figure S3 Competing the neutralizing activities of known MAbs
by D368R. The neutralizing activities of known anti-HIV
neutralizing MAbs were determined in the presence and absence
of the competing D368R gp120 protein. (A) Neutralizing activities
of the anti-V1 MAb P3C8, anti-V3 MAbs P3E1 and 447D, and
MAb 2G12 (recognizes a complex glycan epitope on gp120). (B)
Neutralizing activities of the anti-CD4-BS MAb b12 and of
IgGCD4 are shown. Solid lines and symbols: absence of D368R;
dashed lines and open symbols: presence of D368R.
Found at: doi:10.1371/journal.ppat.1001251.s003 (0.28 MB TIF)
Figure S4 Neutralizing activities of HIV+ plasmas in the
presence of the D368R mutant gp120. The neutralizing activities
of plasmas (A) AC049, (B) AC053, and (C) AC180 against
TRO.11 (red squares), JRFL (blue triangles) and YU2 (green
circles) were determined in the absence (solid lines and symbols)
and presence (dotted lines and open symbols) of D368R gp120.
Patient ID, breadth, and years post infection are shown.
Found at: doi:10.1371/journal.ppat.1001251.s004 (0.30 MB TIF)
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